Navigation Links
Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
Date:11/13/2008

e and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended September 30, 2008, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact:

Paula Izidoro

Investor Relations

858-410-8904


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
2. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
3. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
4. Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008
5. Gen-Probe Announces Webcast of Second Quarter 2008 Earnings Conference Call
6. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
7. Gen-Probe to Webcast Presentation at the William Blair & Company 28th Annual Growth Stock Conference
8. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
9. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
10. Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
11. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3